Brand Name(s) in US
Ticar, Ticillin
Description
Ticarcillin is a semisynthetic β-lactam antibiotic. It is active against
P. aeruginosa,
E. coli,
P. mirabilis,
P. rettgeri, and
K. aerogenes (MICs = 4-125 μg/ml). Topical administration of ticarcillin (2.5 mg per eye) reduces
P. aeruginosa colony count in rabbit eye. Formulations containing ticarcillin have been used in the treatment of a variety of bacterial infections.
Chemical Properties
Ticarcillin disodium salt is White Solid
Originator
Ticar,Beecham,US,1976
Uses
The disodium salt of Ticarcillin, a carboxypenicillin belonging to the beta-lactam class of antibiotics. Ticarcillin is an injectable antibiotic used in the treatment of infections caused by gram-negative bacteria, particularly Pseudomonas aeruginosa.
Uses
The disodium salt of Ticarcillin, a carboxypenicillin belonging to the beta-lactam class of antibiotics. Ticarcillin is an injectable antibiotic used in the treatment of infections caused by gram-nega
tive bacteria, particularly Pseudomonas aeruginosa.
Definition
ChEBI: Ticarcillin disodium is an organic sodium salt. It contains a ticarcillin(2-).
Manufacturing Process
A mixture of monobenzyl-3-thienylmalonate (1.38 g, 5 mmol) and thionyl
chloride (2.5 ml) was warmed at 50°C to 55°C for 1 hour, then at 60°C to
65°C for 10 minutes. The excess of thionyl chloride was removed in vacuo at
not more than 30°C, the last traces being removed by codistillation with dry
benzene (1 ml) under high vacuum, leaving monobenzyl3-thienylmalonyl
chloride as a yellow oil.
The acid chloride obtained as described above was dissolved in dry acetone
(10 ml) and added in a steady stream to a stirred solution of 6-
aminopenicillanic acid (1.08 g, 5 mmol) in a mixture of N sodium bicarbonate
(15 ml) and acetone (5 ml). After the initial reaction the reaction mixture was
stirred at room temperature for 45 minutes, then washed with ether (3 x 25
ml). Acidification of the aqueous solution with N hydrochloric acid (11 ml) to
pH 2 and extraction with ether (3 x 15 ml) gave an ethereal extract which
was decolorized with a mixture of activated charcoal and magnesium sulfate
for 5 minutes.
The resulting pale yellow ethereal solution was shaken with sufficient N
sodium bicarbonate (4 ml) to give an aqueous extract of pH 7 to 7.5. This
extract was concentrated to syrup at low temperature and pressure, then
isopropanol was added with stirring until the mixture contained about 10%
water.
Crystallization was initiated, and completed at about 0°C overnight, to give
the sodium salt of α-(benzyloxycarbonyl)-3-thienylmethylpenicillin as white
crystals in 50% weight yield. This product was estimated by colorimetric assay
with hydroxylamine to contain 91% of the anhydrous sodium salt.
A solution of the sodium salt of α-(benzyloxycarbonyl)-3-
thienylmethylpenicillin (2.13 g, 4.3 mmol) in water (30 ml) was added to a
suspension of 5% palladium on calcium carbonate (10.65 g) in water (32 ml)
which had been prehydrogenated for 1 hour.
The mixture was then hydrogenated at just above atmospheric pressure for 1
1/2 hours and filtered through a Dicalite bed. The clear filtrate was
evaporated at low temperature and pressure, and the residue dried in vacuo
over phosphorus pentoxide, to give 1.64 g of the salt of α-(3-
thienyl)methylpenicillin as a white solid.
Colorimetric assay with hydroxylamine showed this salt to contain 94% of the anhydrous penicillin. Paper chromatography showed complete reduction of the
benzyl group.
Therapeutic Function
Antibiotic
General Description
Ticarcillin was synthesized by Beecham Research Laboratories in 1971. The phenyl residue of carbenicillin was replaced by the 3-thienyl moiety. Ticarcillin shows almost the same activity as carbenicillin against gram-positive bacteria and a twofold higher activity against gram-negative bacteria. Its in vivo activity against Pseudomonas aeruginosa infections in mice is fourfold higher than that of sulbenicillin. Ticarcillin is used to treat sepsis, urinary tract infections, and serious Pseudomonas aeruginosa, Escherichia coli, Proteus, and Enterobacter infections in leukemic and other cancer patients.
